Sponsors (11)
The bill improves drug traceability, recall speed, and consumer access to supply-chain information while simplifying some import labeling rules — but it imposes compliance costs and administrative burdens that may strain small producers, raise proprietary concerns, and complicate customs enforcement.
Patients (including those with chronic conditions) and hospitals can trace a drug's origin and manufacturing facility more easily, enabling faster, more precise recalls and reducing exposure to contaminated products and associated shortages.
Manufacturers and importers can rely on FD&C Act labeling instead of separate Tariff Act markings, lowering customs-related administrative costs and potentially speeding imported drugs' availability to patients and health systems.
Consumers (patients) gain greater transparency through labeling or QR/links that let them verify supply-chain information and make more informed choices about drug sources.
Small and larger drug manufacturers and distributors will incur labeling, IT, and compliance costs that increase operational expenses and could be passed on to consumers or taxpayers.
Smaller producers may struggle with the one-year implementation window and new requirements, risking supply timing, packaging disruptions, or reduced product availability for hospitals and patients.
Suppliers that must identify a single "original manufacturer" will face administrative burdens reconciling complex global supply chains, complicating compliance especially for small firms.
Based on analysis of 3 sections of legislative text.
Requires finished prescription and over‑the‑counter drug labels (and in many cases API labels) to identify the original manufacturers and key supply‑chain entities by name, place of business, and a unique facility identifier or by providing electronic access to that information. The law lets manufacturers use links, barcodes, or QR codes that point to a searchable portal, and requires paper/package‑insert copies on request. The Department of Health and Human Services must write implementing regulations, which cannot take effect sooner than one year after final publication; the rule will apply to drugs made on or after that effective date. The bill also exempts finished drug products that meet the new labeling rule from separate customs country‑of‑origin marking requirements under the Tariff Act.
Introduced February 5, 2026 by Richard Lynn Scott · Last progress February 5, 2026